Bone Biologics (BBLG) Cash from Investing Activities (2014 - 2015)
Bone Biologics (BBLG) reported Cash from Investing Activities of -$504.0 for Q1 2015, down 102.68% year-over-year from $18820.0 in Q1 2014, and up 95.77% quarter-over-quarter from -$11901.0 in Q4 2014.
Bone Biologics (BBLG) Cash from Investing Activities (2014 - 2015) Analysis & Trends
Bone Biologics (BBLG) has 2 years of Cash from Investing Activities data on file, last reported at -$504.0 in Q1 2015.
- Cash from Investing Activities for Q1 2015 came in at -$504.0, down 102.68% year-over-year; the trailing twelve-month figure through Dec 2015 was -$504.0 (down 101.98% YoY), and the FY2015 annual result was -$504.0, down 101.98% from the prior year.
- Cash from Investing Activities improved to -$504.0 in Q1 2015 per BBLG's latest filing, from -$11901.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $18820.0 in Q1 2014 and troughed at -$11901.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | -504.00 |
| Mar 31, 2015 | -504.00 |
| Dec 31, 2014 | -11,901.00 |
| Dec 31, 2014 | -11,901.00 |
| Jun 30, 2014 | 18,557.00 |
| Jun 30, 2014 | 18,557.00 |
| Mar 31, 2014 | 18,820.00 |
| Mar 31, 2014 | 18,820.00 |